Based on our current understanding of luteolin, it is reasonable to postulate that PP2A, HSP90, Akt, Ask1, p38, and JNK might represent potential therapeutic targets for the treatment of RCC. The gene discussed is PTPA; the disease is renal cell carcinoma.